Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells
J. Ptáček, Ivan Šnajdr, Jiří Schimer, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4720-4720
Open Access | Times Cited: 17

Showing 17 citing articles:

Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers DS-103 as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties
Daniel Stopper, Lukas Biermann, P. R. Watson, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 2
Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase 6
Beate König, P. R. Watson, Nina Reßing, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 19, pp. 13821-13837
Open Access | Times Cited: 24
Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases
D.W. Christianson
Accounts of Chemical Research (2024) Vol. 57, Iss. 8, pp. 1135-1148
Closed Access | Times Cited: 11
Significance of Five-Membered Heterocycles in Human Histone Deacetylase Inhibitors
Anton Frühauf, Martin Behringer, Franz‐Josef Meyer‐Almes
Molecules (2023) Vol. 28, Iss. 15, pp. 5686-5686
Open Access | Times Cited: 16
Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism
Lena Ripa, Jenny Sandmark, Glyn A. Hughes, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 20, pp. 14188-14207
Closed Access | Times Cited: 15
Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6)
L. Motlova, Ivan Šnajdr, Zsófia Kutil, et al.
ACS Chemical Biology (2023) Vol. 18, Iss. 7, pp. 1594-1610
Open Access | Times Cited: 11
Benzothiazole derivatives as histone deacetylase inhibitors for the treatment of autosomal dominant polycystic kidney disease
Xudong Cao, Zhiyuan Fan, Lingfang Xu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116428-116428
Closed Access | Times Cited: 4
Small molecules targeting HDAC6 for cancer treatment: Current progress and novel strategies
Ziqian Huang, Ling Li, Binbin Cheng, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117218-117218
Open Access | Times Cited: 4
Efficacy of a New Selective Indole-based Histone Deacetylase 10 Inhibitor in Targeted Anticancer Therapy
Amer H. Taráwneh, Salah A. Al‐Trawneh, Talha Z. Yesiloglu, et al.
Research Square (Research Square) (2025)
Closed Access
Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups
Gustavo Salgado Pires, Heber Victor Tolomeu, Daniel A. Rodrigues, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 4, pp. 577-577
Open Access
Histone deacetylase 10: A polyamine deacetylase from the crystal structure to the first inhibitors
Chiara Lambona, Clemens Zwergel, Rossella Fioravanti, et al.
Current Opinion in Structural Biology (2023) Vol. 82, pp. 102668-102668
Open Access | Times Cited: 8
2-(Difluoromethyl)-1,3,4-oxadiazoles: The Future of Selective Histone Deacetylase 6 Modulation?
Beate König, Finn K. Hansen
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 3, pp. 899-903
Open Access | Times Cited: 2
Lack of effect from genetic deletion of Hdac6 in a humanized mouse model of CMT2D
Abigail L. D. Tadenev, Courtney L. Hatton, Robert W. Burgess
Journal of the Peripheral Nervous System (2024) Vol. 29, Iss. 2, pp. 213-220
Closed Access | Times Cited: 2
The Importance of the “Time Factor” for the Evaluation of Inhibition Mechanisms: The Case of Selected HDAC6 Inhibitors
Edoardo Cellupica, Gianluca Caprini, Gianluca Fossati, et al.
Biology (2023) Vol. 12, Iss. 8, pp. 1049-1049
Open Access | Times Cited: 3
Difluoromethyl-1,3,4-oxadiazoles are selective, mechanism-based, and essentially irreversible inhibitors of histone deacetylase 6
Beate König, P. R. Watson, Nina Reßing, et al.
(2023)
Open Access | Times Cited: 2
Difluoromethyl-1,3,4-oxadiazoles are selective, mechanism-based, and essentially irreversible inhibitors of histone deacetylase 6
Beate König, P. R. Watson, Nina Reßing, et al.
(2023)
Open Access | Times Cited: 1
Editorial for Special Issue—“Early-Stage Drug Discovery: Advances and Challenges”
Wolfgang Sippl
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6516-6516
Open Access
Page 1

Scroll to top